Skip to main content
Top
Published in: Endocrine Pathology 1/2016

01-03-2016

Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism

Authors: Bernardo Dias Pereira, Luísa Raimundo, Ozgur Mete, Ana Oliveira, Jorge Portugal, Sylvia L. Asa

Published in: Endocrine Pathology | Issue 1/2016

Login to get access

Abstract

Thyrotropin (TSH)-secreting pituitary adenomas are exceedingly rare at the pediatric age and no cases of co-secretion with other pituitary hormones in these tumors have been described in this age range. We present a case of a monomorphous plurihormonal pituitary adenoma that co-secreted TSH and GH in a pediatric patient. A 13-year-old male presented with increasing height velocity (17.75 cm/year, 9.55SD), weight loss, and visual impairment. Initial biochemical evaluations revealed secondary hyperthyroidism. A giant pituitary tumor compressing the surrounding structures was detected by magnetic resonance, and a transsphenoidal surgery was initially performed. Pathological examinations revealed an atypical, monomorphous plurihormonal Pit-1 lineage tumor with mixed features of silent subtype 3 adenoma and acidophil stem cell adenoma. In the postoperative period, secondary hyperthyroidism recurred with high levels of both GH and IGF1. In addition, due to tumor re-growth, a multimodality treatment plan was undertaken including surgery, somatostatin analogs, and radiotherapy. We report the first pediatric case of a plurihormonal TSH- and GH-secreting pituitary adenoma, further expanding the clinical manifestations of pediatric pituitary tumors. Comprehensive pathological evaluation and close follow-up surveillance are crucial to the prompt delivery of the best therapeutic options in the context of this particularly aggressive pituitary tumor.
Literature
1.
go back to reference Jailer JW, Holub DA. Remission of Graves disease following radiotherapy of a pituitary neoplasm. Am J Med 28:497–500, 1960.CrossRefPubMed Jailer JW, Holub DA. Remission of Graves disease following radiotherapy of a pituitary neoplasm. Am J Med 28:497–500, 1960.CrossRefPubMed
2.
go back to reference Salvatore D, Davies TF, Schlumberger MJ, Hay ID, Larsen PR. Thyroid Physiology and Diagnostic Evaluation of Patients with Thyroid Disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 11th ed. Salvatore D, Davies TF, Schlumberger MJ, Hay ID, Larsen PR. Thyroid Physiology and Diagnostic Evaluation of Patients with Thyroid Disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 11th ed.
3.
go back to reference Mindermann T, Wilson CB. Age-related and gender related occurrence of pituitary adenomas. Clin Endocrinol 41:359–364, 1994.CrossRef Mindermann T, Wilson CB. Age-related and gender related occurrence of pituitary adenomas. Clin Endocrinol 41:359–364, 1994.CrossRef
4.
go back to reference Rouach V, Greenman Y. Thyrotropin-Secreting Pituitary Tumours. In: Melmed S, ed. The Pituitary. 3rd ed. Rouach V, Greenman Y. Thyrotropin-Secreting Pituitary Tumours. In: Melmed S, ed. The Pituitary. 3rd ed.
5.
go back to reference Nyhan WL, Green M. Hyperthyroidism in a patient with a pituitary adenoma. J Pediatr 65:583–589, 1964.CrossRefPubMed Nyhan WL, Green M. Hyperthyroidism in a patient with a pituitary adenoma. J Pediatr 65:583–589, 1964.CrossRefPubMed
6.
go back to reference Suntornlohanakul S, Vasiknanont P, Mo-Suwan L, Phuenpathom N; Chongchitnant N. TSH secreting pituitary adenoma in children: a case report. J Med A Thai 73:175–178, 1990. Suntornlohanakul S, Vasiknanont P, Mo-Suwan L, Phuenpathom N; Chongchitnant N. TSH secreting pituitary adenoma in children: a case report. J Med A Thai 73:175–178, 1990.
7.
go back to reference Polak M, Bertherat J, Li JY, Kujas M, Le Dafniet M, Weizani H, et al. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201–995 treatment. Acta Endocrinol-Cop 124:479–486, 1991. Polak M, Bertherat J, Li JY, Kujas M, Le Dafniet M, Weizani H, et al. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201–995 treatment. Acta Endocrinol-Cop 124:479–486, 1991.
8.
go back to reference Stanley JM, Najjar SS. Hyperthyroidism secondary to a TSH-secreting pituitary adenoma in a 15-year-old male. Clin Pediatr 30:109–111, 1991.CrossRef Stanley JM, Najjar SS. Hyperthyroidism secondary to a TSH-secreting pituitary adenoma in a 15-year-old male. Clin Pediatr 30:109–111, 1991.CrossRef
9.
go back to reference Avramides A, Karapiperis A, Triantafyllidou E, Vayas S, Moshidou A, Vyzantiadis A. TSH-secreting pituitary macroadenoma in an 11-year-old girl. Acta Paediatr 81:1058–1060, 1992.CrossRefPubMed Avramides A, Karapiperis A, Triantafyllidou E, Vayas S, Moshidou A, Vyzantiadis A. TSH-secreting pituitary macroadenoma in an 11-year-old girl. Acta Paediatr 81:1058–1060, 1992.CrossRefPubMed
10.
go back to reference Phillip M, Hershkovitz E, Kornmehl P, Cohen A, Leiberman E. Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. J Pediatr Endocrinol Metabol 8:47–50, 1995.CrossRef Phillip M, Hershkovitz E, Kornmehl P, Cohen A, Leiberman E. Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. J Pediatr Endocrinol Metabol 8:47–50, 1995.CrossRef
11.
go back to reference Gannage MH, Maacaron C, Okais N, Halaby G. Thyroid-stimulating hormone hypophyseal adenoma. A case report. J Med Lib 45:97–101, 1997. Gannage MH, Maacaron C, Okais N, Halaby G. Thyroid-stimulating hormone hypophyseal adenoma. A case report. J Med Lib 45:97–101, 1997.
12.
go back to reference Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumours: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metabol 84:476–486, 1999.CrossRef Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumours: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metabol 84:476–486, 1999.CrossRef
13.
go back to reference Kessler M, David R, Pawelczak M, Hanono A, Shah B. Thyrotropin-secreting pituitary adenoma in an adolescent boy: challenges in management. Pediatrics 126:e474-478, 2010.CrossRefPubMed Kessler M, David R, Pawelczak M, Hanono A, Shah B. Thyrotropin-secreting pituitary adenoma in an adolescent boy: challenges in management. Pediatrics 126:e474-478, 2010.CrossRefPubMed
14.
go back to reference Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs. Thyroid 22:1076–1079, 2012.CrossRefPubMed Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs. Thyroid 22:1076–1079, 2012.CrossRefPubMed
15.
go back to reference Nakayama Y, Jinguji S, Kumakura S, Nagasaki K, Natsumeda M, Yoneoka Y, et al. Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report. Pituitary 15:110–115, 2012.CrossRefPubMed Nakayama Y, Jinguji S, Kumakura S, Nagasaki K, Natsumeda M, Yoneoka Y, et al. Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report. Pituitary 15:110–115, 2012.CrossRefPubMed
16.
go back to reference Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610–638, 1996.PubMed Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610–638, 1996.PubMed
17.
go back to reference Sanno N, Teramoto A, Matsuno A, Takekoshi S, Osamura RY. GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas. J Clin Endocrinol Metabol 8:2518–2522, 1995. Sanno N, Teramoto A, Matsuno A, Takekoshi S, Osamura RY. GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas. J Clin Endocrinol Metabol 8:2518–2522, 1995.
18.
go back to reference Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metabol 77:1275–1280, 1993. Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metabol 77:1275–1280, 1993.
19.
go back to reference Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148:433–442, 2003.CrossRefPubMed Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148:433–442, 2003.CrossRefPubMed
20.
go back to reference Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69-R78, 2012.CrossRefPubMed Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69-R78, 2012.CrossRefPubMed
21.
go back to reference Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W. Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29:511–524, 2005.CrossRefPubMed Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W. Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29:511–524, 2005.CrossRefPubMed
22.
go back to reference Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71:92–99, 2009.CrossRef Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71:92–99, 2009.CrossRef
23.
go back to reference Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, et al. A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metabol 66:1111–1118, 1988.CrossRef Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, et al. A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metabol 66:1111–1118, 1988.CrossRef
24.
go back to reference Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47:761–771, 1981.CrossRefPubMed Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47:761–771, 1981.CrossRefPubMed
25.
go back to reference Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metabol 97:E663-E670, 2012.CrossRef Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metabol 97:E663-E670, 2012.CrossRef
26.
go back to reference Beck-Peccoz P, Persani L. Thyrotropinomas. Endocrinol Metabol Clin North Am 37:123–134, 2008.CrossRef Beck-Peccoz P, Persani L. Thyrotropinomas. Endocrinol Metabol Clin North Am 37:123–134, 2008.CrossRef
27.
go back to reference Colao A, Pivonello R, Di Somma C, Tauchmanovà L, Savastano S, Lombardi G. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf) 66:714–722, 2007.CrossRef Colao A, Pivonello R, Di Somma C, Tauchmanovà L, Savastano S, Lombardi G. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf) 66:714–722, 2007.CrossRef
29.
go back to reference Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr Pract 17:636–646, 2011.CrossRefPubMed Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr Pract 17:636–646, 2011.CrossRefPubMed
30.
go back to reference Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays—a 2009 update. Growth Horm IGF1 Res 20:8–18, 2010.CrossRef Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays—a 2009 update. Growth Horm IGF1 Res 20:8–18, 2010.CrossRef
31.
go back to reference Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL. Variability and Reliability of single Serum IGF-I Measurements: Impact on Determining Predictability of Risk Ratios in Disease Development. J Clin Endocrinol Metab 89:2271–2274, 2004.PubMedCentralCrossRefPubMed Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL. Variability and Reliability of single Serum IGF-I Measurements: Impact on Determining Predictability of Risk Ratios in Disease Development. J Clin Endocrinol Metab 89:2271–2274, 2004.PubMedCentralCrossRefPubMed
32.
go back to reference Mete O, Gomez-Hernazdez K, Ezzat S, Asa S. Pituitary Silent Subtype III Adenomas are not Always Silent and Represent Pit-1 Lineage Adenomas. Mod Pathol 28(S2):138A, 2015. Mete O, Gomez-Hernazdez K, Ezzat S, Asa S. Pituitary Silent Subtype III Adenomas are not Always Silent and Represent Pit-1 Lineage Adenomas. Mod Pathol 28(S2):138A, 2015.
33.
go back to reference Lloyd RV, Kovacs K, Young WF, Farrell WE, Asa SL, Trouillas J, et al. Pituitary Tumours. In: Delellies RA, Lloyd RV, Heitz PU, Eng C, eds. Tumors of Endocrine Organs, 2004. Lloyd RV, Kovacs K, Young WF, Farrell WE, Asa SL, Trouillas J, et al. Pituitary Tumours. In: Delellies RA, Lloyd RV, Heitz PU, Eng C, eds. Tumors of Endocrine Organs, 2004.
34.
go back to reference Yamaguchi-Okada M, Inoshita N, Nishioka H, Fukuhara N, Yamada S. Clinicopathological analysis of nonfunctioning pituitary adenomas in patients younger than 25 years of age. J Neuros Pediatr 9:511–516, 2012.CrossRef Yamaguchi-Okada M, Inoshita N, Nishioka H, Fukuhara N, Yamada S. Clinicopathological analysis of nonfunctioning pituitary adenomas in patients younger than 25 years of age. J Neuros Pediatr 9:511–516, 2012.CrossRef
36.
go back to reference Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumors for personalized therapeutic strategies. Eur J Endocrinol 170:R121-R132, 2014.CrossRefPubMed Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumors for personalized therapeutic strategies. Eur J Endocrinol 170:R121-R132, 2014.CrossRefPubMed
37.
go back to reference Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18:2543–2552, 2004.CrossRefPubMed Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18:2543–2552, 2004.CrossRefPubMed
38.
go back to reference Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li, CC, Hirokawa M, Kovacs K, Ezzat S, Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89:1904–11, 2004.CrossRefPubMed Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li, CC, Hirokawa M, Kovacs K, Ezzat S, Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89:1904–11, 2004.CrossRefPubMed
39.
go back to reference Macchia E, Gasperi M, Lombardi M, Morselli L, Pinchera A, Acerbi G, et al. Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: A single center experience. J Endocrinol Inv 32:773–779, 2009.CrossRef Macchia E, Gasperi M, Lombardi M, Morselli L, Pinchera A, Acerbi G, et al. Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: A single center experience. J Endocrinol Inv 32:773–779, 2009.CrossRef
40.
go back to reference Kuzuya N, Inoue K, Ishibashi M, Murayama Y, Koide Y, Ito K, et al. Endocrine and Immunohistochemical Studies on Thyrotropin (TSH)-Secreting Pituitary Adenomas: Responses of TSH, a-Subunit, and Growth Hormone to Hypothalamic Releasing Hormones and Their Distribution in Adenoma Cells. J Clin Endocrinol Metab 71:1103–1111, 1990.CrossRefPubMed Kuzuya N, Inoue K, Ishibashi M, Murayama Y, Koide Y, Ito K, et al. Endocrine and Immunohistochemical Studies on Thyrotropin (TSH)-Secreting Pituitary Adenomas: Responses of TSH, a-Subunit, and Growth Hormone to Hypothalamic Releasing Hormones and Their Distribution in Adenoma Cells. J Clin Endocrinol Metab 71:1103–1111, 1990.CrossRefPubMed
41.
go back to reference Jaquet P, Hassoun J, Delori P, Gunz G, Grisoli F, Weintraub BD. A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies. J Clin Endocrinol Metab 59:817–824, 1984.CrossRefPubMed Jaquet P, Hassoun J, Delori P, Gunz G, Grisoli F, Weintraub BD. A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies. J Clin Endocrinol Metab 59:817–824, 1984.CrossRefPubMed
42.
go back to reference Kovacs K, Horvath E, Ezrin C, Weiss MH. Adenoma of the human pituitary producing growth hormone and thyrotropin. A histologic, immunocytologic and fine-structural study. Virch Arch 395:59–68, 1982.CrossRef Kovacs K, Horvath E, Ezrin C, Weiss MH. Adenoma of the human pituitary producing growth hormone and thyrotropin. A histologic, immunocytologic and fine-structural study. Virch Arch 395:59–68, 1982.CrossRef
43.
go back to reference Bertholon-Grégoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J. Mono and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol 140:519–527, 1999.CrossRefPubMed Bertholon-Grégoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J. Mono and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol 140:519–527, 1999.CrossRefPubMed
44.
go back to reference Skorić T, Korsić M, Zarković K, Plavsić V, Besenski N, Breskovac L, et al. Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma. Eur J Endocrinol 140:528–537, 1999.CrossRefPubMed Skorić T, Korsić M, Zarković K, Plavsić V, Besenski N, Breskovac L, et al. Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma. Eur J Endocrinol 140:528–537, 1999.CrossRefPubMed
45.
go back to reference Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 62:210–216, 2005.CrossRef Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 62:210–216, 2005.CrossRef
46.
go back to reference Brada M, Jankowska P. Radiotherapy for pituitary adenomas. Endocrinol Metabol Clin North Am 37:263–275, 2008.CrossRef Brada M, Jankowska P. Radiotherapy for pituitary adenomas. Endocrinol Metabol Clin North Am 37:263–275, 2008.CrossRef
47.
go back to reference Bondanelli M, Bonadonna S, Ambrosio MR, Doga M, Gola M, Onofri A, et al. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism 54:1174–1180, 2005.CrossRefPubMed Bondanelli M, Bonadonna S, Ambrosio MR, Doga M, Gola M, Onofri A, et al. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism 54:1174–1180, 2005.CrossRefPubMed
48.
go back to reference Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247–271, 2011.CrossRefPubMed Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247–271, 2011.CrossRefPubMed
49.
go back to reference Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene. Endocr Rev 34:239–277, 2013.PubMedCentralCrossRefPubMed Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene. Endocr Rev 34:239–277, 2013.PubMedCentralCrossRefPubMed
50.
go back to reference Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891–1896, 2007.CrossRefPubMed Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891–1896, 2007.CrossRefPubMed
Metadata
Title
Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism
Authors
Bernardo Dias Pereira
Luísa Raimundo
Ozgur Mete
Ana Oliveira
Jorge Portugal
Sylvia L. Asa
Publication date
01-03-2016
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2016
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9395-2

Other articles of this Issue 1/2016

Endocrine Pathology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.